The goal of this study is to determine the feasibility of intravenous @entity136 and an intraperitoneal @entity902 agent in the treatment of @entity1 with @entity43 . We performed a retrospective chart review of @entity1 with primary, persistent or recurrent @entity43 , who received intravenous @entity136 and an intraperitoneal @entity902 agent. @entity1 received @entity136 (750 mg/m  ) intravenous on days 1 and 8 and @entity900 (100 or 60 mg/m  ) intraperitoneal on day 1 every 21 - 28 days. An alternate regimen was composed of @entity136 (750 mg/m  ) intravenous and @entity3003 (AUC 5) intraperitoneal on day 1 every 21 days. Dose reductions occurred at the discretion of the prescribing physician.Intravenous @entity136 and an intraperitoneal @entity902 agent were administered to 12 @entity1 with advanced primary or recurrent @entity43 . Myelosuppression was the most common @entity137 . Grade 3 or 4 @entity882 , @entity1398 and @entity417 occurred in 7, 8 and 2 @entity1 respectively. Dose reductions were required in 7 of 12 @entity1 . 10 of 12 @entity1 received 6 cycles of the regimen. Treatment was discontinued prior to 6 cycles in 2 of 12 @entity1 secondary to progression in one case and to grade 4 @entity1398 and @entity882 in another.The combination of intravenous @entity136 and an intraperitoneal @entity902 agent appears to be a feasible regimen in @entity1 with @entity43 . The most common @entity137 was myelosuppression, which resulted in dose reductions in almost half of the @entity1 .

Feasibility of intravenous XXXX and an intraperitoneal @entity902 agent in the treatment of @entity43 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
